Latest News on ORIC

Financial News Based On Company


Advertisement
Advertisement

Oric Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $21.64, Implies 188% Upside

https://www.tradingview.com/news/tradingview:02122c2818149:0-oric-pharmaceuticals-inc-stock-12-month-price-target-cut-to-21-79-implies-190-upside/
Oric Pharmaceuticals, Inc.'s average 12-month price target has been reduced from $22.75 to $21.64, according to 14 analysts, with forecasts ranging from $14 to $27 per share. This updated target suggests a potential upside of approximately 188% based on the November 16 closing price. The consensus rating for the stock remains a "Buy" from 16 covering analysts.

Wedbush reiterates Oric Pharmaceuticals stock rating on trial data By Investing.com

https://ca.investing.com/news/stock-market-news/wedbush-reiterates-oric-pharmaceuticals-stock-rating-on-trial-data-93CH-4964081
Wedbush reiterated an Outperform rating and $14.00 price target on ORIC Pharmaceuticals following the company’s third-quarter 2026 earnings update on rinzimetostat trial data. The company presented promising longer-term follow-up data for rinzimetostat in metastatic castration-resistant prostate cancer, showing favorable progression-free survival rates and a good safety profile. Upcoming catalysts include the Phase 3 MEVPRO-1 readout for mevrometostat in February 2027, which is expected to reflect positively on rinzimetostat.

Oric Pharmaceuticals (NASDAQ:ORIC) Earns Buy Rating from BTIG Research

https://www.marketbeat.com/instant-alerts/analyst-oric-pharmaceuticals-nasdaq-oric-earns-buy-rating-from-btig-research-2026-11-17/
BTIG Research has reiterated its "Buy" rating for Oric Pharmaceuticals (NASDAQ:ORIC), setting a price target of $26, which suggests a significant upside. Despite the positive analyst sentiment, the company reported a quarterly loss exceeding expectations, and its CFO sold a substantial number of shares in August. Oric Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on developing cancer medicines aimed at overcoming treatment resistance.

Oric Pharmaceuticals stock maintained at Buy by BTIG, $26 target

https://ca.investing.com/news/stock-market-news/oric-pharmaceuticals-stock-maintained-at-buy-by-btig-26-target-93CH-4963759
BTIG has reiterated its Buy rating on Oric Pharmaceuticals (NASDAQ:ORIC) stock and maintained a $26.00 price target following the company's third-quarter earnings report. The company shared positive rinzimetostat data, showing significant progression-free survival in prostate cancer, and updated enozertinib data supporting advancement into a Phase 3 trial. Oric Pharmaceuticals also reported approximately $345 million in cash, funding operations into the second half of 2028, and is considered undervalued by InvestingPro analysis.

ORIC Pharmaceuticals Q3 Results: Loss widens to $0.44 per share

https://scanx.trade/stock-market-news/companies/oric-pharmaceuticals-q3-results-loss-widens-0-44-per-share/56417970
ORIC Pharmaceuticals reported a Q3 loss of $(0.44) per share, missing analyst estimates of $(0.39) by 12.82%. The company's losses widened by 33.33% year-over-year compared to $(0.33) per share in the same period last year, indicating increased cash burn or operational costs. This performance highlights a challenging quarter and suggests market expectations were not fully aligned with the company's financial trajectory.
Advertisement

ORIC: Rinzimetostat Phase 3 began as enozertinib posted strong systemic and CNS responses

https://www.tradingview.com/news/urn:summary_document_report:quartr.com:3955169:0-oric-rinzimetostat-phase-3-began-as-enozertinib-posted-strong-systemic-and-cns-responses/
ORIC Pharmaceuticals announced that its drug, Rinzimetostat, has entered Phase 3 trials, showing promising preliminary durability and safety data for metastatic Castration-Resistant Prostate Cancer (mCRPC). Additionally, enozertinib reported strong systemic and central nervous system (CNS) response rates. The company expects its current cash and investments of $345.4 million to fund operations until the second half of 2028.

Oric Pharmaceuticals (NASDAQ:ORIC) Issues Earnings Results

https://www.marketbeat.com/instant-alerts/earnings-oric-pharmaceuticals-nasdaq-oric-issues-earnings-results-2026-11-16/
Oric Pharmaceuticals (NASDAQ:ORIC) announced quarterly earnings of ($0.44) per share, missing consensus estimates by $0.05, which led to a 4.3% drop in share price to $7.52 on Monday. Despite the miss, analysts maintain a "Moderate Buy" rating with an average price target of $21.25. Insider transactions also showed the CFO selling 14,000 shares for $189,420.00 in October.

ORIC Pharmaceuticals, Inc. (ORIC) Misses Q3 EPS by 6c

https://www.streetinsider.com/Earnings/ORIC+Pharmaceuticals%2C+Inc.+%28ORIC%29+Misses+Q3+EPS+by+6c/27357023.html
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) reported its Q3 earnings per share (EPS), which came in at ($0.44). This figure was $0.06 worse than the analyst estimate of ($0.38). The stock price for ORIC was $7.52, down 4.33% on the day.

ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates

https://www.manilatimes.net/2026/11/17/tmt-newswire/globenewswire/oric-pharmaceuticals-reports-third-quarter-2026-financial-results-and-provides-operational-and-rinzimetostat-program-updates/2471393
ORIC Pharmaceuticals reported its third-quarter 2026 financial results, highlighting significant progress in its rinzimetostat and enozertinib programs. Key updates include the initiation of the Himalayas-1 global Phase 3 trial for rinzimetostat in mCRPC, updated rinzimetostat combination data showing differentiated safety and consistent efficacy with competitor PRC2 inhibitors, and promising enozertinib data for 1L EGFR atypical NSCLC, leading to plans for the Redwood-1 global Phase 3 trial. The company's cash and investments of approximately $345 million are expected to fund operations into the second half of 2028.

A fund adviser and its control person each report 2.9% of Oric Pharmaceuticals (ORIC).

https://www.stocktitan.net/sec-filings/ORIC/schedule-13g-a-oric-pharmaceuticals-inc-amended-passive-investment-di-3403b3f99971.html
EcoR1 Capital, LLC, its control person Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. have filed an amended ownership report for Oric Pharmaceuticals (ORIC). EcoR1 and Nodelman each reported a beneficial ownership of 3,028,116 shares, representing 2.9% of the class, while Qualified Fund reported 2,885,435 shares, or 2.8%. The filing clarifies their shared voting and dispositive power and their relationship, with EcoR1 serving as the investment adviser and general partner, and Nodelman as the control person of EcoR1.
Advertisement

ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates

https://www.globenewswire.com/news-release/2026/11/16/3404112/0/en/oric-pharmaceuticals-reports-third-quarter-2026-financial-results-and-provides-operational-and-rinzimetostat-program-updates.html
ORIC Pharmaceuticals reported its Q3 2026 financial results and provided updates on its rinzimetostat and enozertinib programs. The company initiated a global Phase 3 trial for rinzimetostat in mCRPC and announced plans for a Phase 3 trial for enozertinib in 1L EGFR atypical NSCLC, backed by approximately $345 million in cash and investments. Clinical data presented for both drug candidates reinforce confidence in their potential best-in-class profiles and differentiated safety and efficacy compared to competitors.

Discipline and Rules-Based Execution in ORIC Response

https://news.stocktradersdaily.com/news_release/150/Discipline_and_Rules-Based_Execution_in_ORIC_Response_111226094201_1794537721.html
This article provides an in-depth analysis of Oric Pharmaceuticals Inc. (NASDAQ: ORIC), highlighting divergent sentiment across all trading horizons and suggesting choppy conditions for the stock. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—complete with entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal analysis, identifying support and resistance levels for near-term, mid-term, and long-term outlooks.

Oric Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $22.75, Implies 153% Upside

https://www.tradingview.com/news/tradingview:523bdba183b68:0-oric-pharmaceuticals-inc-stock-12-month-price-target-raised-to-22-75-implies-153-upside/
Oric Pharmaceuticals, Inc. (ORIC) has seen its average price target raised to $22.75 from $21.71 by 12 analysts, with forecasts ranging from $14 to $27 per share. This new target implies a potential upside of approximately 153% based on the Nov. 11 closing price. The consensus rating from 14 analysts remains "Buy," with 13 Buys and 1 Hold.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

https://www.manilatimes.net/2026/11/07/tmt-newswire/globenewswire/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/2464358
ORIC Pharmaceuticals announced inducement grants to a new non-executive employee, consisting of 14,800 non-qualified stock options and 2,400 restricted stock units. These grants were made on November 2, 2026, under the company's 2022 Inducement Equity Incentive Plan and approved by the Compensation Committee in accordance with Nasdaq Rule 5635(c)(4). The grants are intended as a material inducement for employment and are subject to specific vesting schedules.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

https://www.globenewswire.com/news-release/2026/11/06/3397898/0/en/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
ORIC Pharmaceuticals announced that on November 2, 2026, it granted 14,800 non-qualified stock options and 2,400 restricted stock units to a new non-executive employee. These inducement grants, approved by ORIC's Compensation Committee and in accordance with Nasdaq Rule 5635(c)(4), are subject to vesting schedules tied to continued employment. The company emphasized its focus on developing treatments for therapeutic resistance in oncology.
Advertisement

Three conference discussions from ORIC will stream online, with replays available for 90 days.

https://www.stocktitan.net/news/ORIC/oric-pharmaceuticals-to-participate-in-upcoming-investor-cutth8veynmq.html
ORIC Pharmaceuticals (Nasdaq: ORIC) announced its management will participate in three investor conferences in November 2026, featuring fireside chats and one-on-one meetings. Webcasts of these discussions will be accessible via the company's investor website, with replays available for 90 days post-event. The conferences include Guggenheim's 3rd Annual Healthcare Innovation Conference, Stifel 2026 Healthcare Conference, and Jefferies London Healthcare Conference.

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

https://www.globenewswire.com/news-release/2026/11/03/3394729/0/en/oric-pharmaceuticals-to-participate-in-upcoming-investor-conferences.html
ORIC Pharmaceuticals, a clinical-stage oncology company, announced its participation in three investor conferences in November: Guggenheim’s 3rd Annual Healthcare Innovation Conference, Stifel 2026 Healthcare Conference, and Jefferies London Healthcare Conference. Management will engage in fireside chats and one-on-one meetings at these events. Webcasts of the fireside chats will be available on the company's website.

Liquidity Mapping Around (ORIC) Price Events

https://news.stocktradersdaily.com/news_release/14/Liquidity_Mapping_Around_ORIC_Price_Events_110226095802_1793674682.html
This article provides a liquidity mapping analysis for Oric Pharmaceuticals Inc. (NASDAQ: ORIC), noting weak near-term and mid-term sentiment, despite a positive long-term outlook. It identifies key support and resistance signals and outlines three AI-generated institutional trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, each with specific entry, target, and stop-loss zones.

ORIC Q3'26 Earnings: revenue estimate is 0 USD

https://www.tradingview.com/news/tradingview:ddddad5731be5:0-oric-q3-26-earnings-revenue-estimate-is-0-usd/
Oric Pharmaceuticals, Inc. (ORIC) is scheduled to release its Q3'26 earnings on November 9, with an expected revenue of 0 USD and an anticipated EPS of (0.39) USD. The article provides a historical overview of reported and estimated revenue and EPS figures, highlighting past EPS surprises.

10-Q: Oric Pharmaceuticals | 10-Q: Q2 2026 Earnings Report

https://www.moomoo.com/news/notice/307825088/oric-pharmaceuticals-10-q-q2-2026-earnings-report
This document is Oric Pharmaceuticals' 10-Q filing for its Q2 2026 earnings report. A 10-Q is a comprehensive quarterly financial report submitted to the Securities and Exchange Commission (SEC) by public companies. It contains unaudited financial statements and provides a continuing view of the company's financial position during the year.
Advertisement

ORIC Pharmaceuticals, Inc. (ORIC) Seasonal returns chart

https://uk.finance.yahoo.com/quote/ORIC/seasonality/
This article from Yahoo Finance presents a seasonal returns chart for ORIC Pharmaceuticals, Inc. (ORIC), showing the average monthly price return from 2020 to 2026. As of the close on November 2nd, ORIC's stock was trading at $9.07, down 1.84%. The page also provides access to summary, news, chart, statistics, and other financial data for ORIC.

ORIC Pharmaceuticals, Inc. (ORIC) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/ORIC/seasonality/
The article provides a seasonal returns chart for ORIC Pharmaceuticals, Inc. (ORIC), displaying average monthly price returns from 2020 to 2026. It includes current stock information, showing ORIC at $9.24 with a 2.78% increase at market close on October 30. The page also features an overnight price from the Blue Ocean ATS.

Wedbush maintains Outperform rating on ORIC Pharmaceuticals, $14 price target

https://www.tradingview.com/news/tradingview:762d33703e8af:0-wedbush-maintains-outperform-rating-on-oric-pharmaceuticals-14-price-target/
Wedbush has reiterated its Outperform rating on ORIC Pharmaceuticals, setting a price target of $14.00, which suggests a 56.3% upside from its recent closing price. This positive outlook is driven by impressive early clinical data for ORIC-944 and ORIC-114, showing strong activity in cancer patients, and the company's strategic focus on therapies addressing resistance mechanisms in oncology.

ORIC Pharmaceuticals, Inc. (ORIC) Options Chain

https://ca.finance.yahoo.com/quote/ORIC/options/?date=1797552000&straddle=false&type=all
This article provides the options chain for ORIC Pharmaceuticals, Inc. (ORIC) on Yahoo Finance. It indicates that as of the given time, there are no calls or puts available in the money for the company's options. The stock price is listed at $8.93, down 0.78%.

H.C. Wainwright Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $27

https://www.moomoo.com/news/post/1002490892/hc-wainwright-maintains-oric-pharmaceuticals-oricus-with-buy-rating-maintains
H.C. Wainwright has reaffirmed its Buy rating on Oric Pharmaceuticals (ORIC.US), maintaining a target price of $27. This continued positive outlook suggests the firm's confidence in the pharmaceutical company's prospects.
Advertisement

ORIC Maintained by Stifel -- Price Target Raised to $18.00

https://www.gurufocus.com/news/9142802/oric-maintained-by-stifel-price-target-raised-to-1800
Stifel's Laura Prendergast maintained a "Buy" rating for ORIC Pharmaceuticals (ORIC) and raised its price target to $18.00 from $14.00, an increase of 28.57%. This positive outlook reflects optimism about ORIC's growth potential in the biotechnology sector, despite the company being unprofitable and cash-flow-negative, with a GF Score™ of 40/100 indicating mixed financial performance. Insider activity shows significant selling, which could be a concern for investors.

Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), Oric Pharmaceuticals (ORIC)

https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/8470280/analysts-are-bullish-on-top-healthcare-stocks-perspective-therapeutics-catx-oric-pharmaceuticals-oric/
Two analysts from UBS and BTIG have issued bullish ratings on healthcare stocks Perspective Therapeutics (CATX) and Oric Pharmaceuticals (ORIC). UBS analyst David Dai maintained a Buy rating on Perspective Therapeutics with an $8.00 price target, while BTIG's Jeet Mukherjee maintained a Buy rating on Oric Pharmaceuticals with a $26.00 price target. Both companies currently hold a Strong Buy analyst consensus rating, indicating significant upside potential.

Oric Pharmaceuticals (NASDAQ:ORIC) Stock Crosses Below 200-Day Moving Average - Should You Sell?

https://www.marketbeat.com/instant-alerts/price-oric-pharmaceuticals-nasdaq-oric-stock-crosses-below-200-day-moving-average-should-you-sell-2026-10-27/
Oric Pharmaceuticals (NASDAQ:ORIC) stock recently fell below its 200-day moving average, trading at $8.95 after hitting a low of $8.88, with a significant volume of 6.9 million shares. Despite this decline, analysts largely maintain a "Moderate Buy" rating with an average price target of $21.50, driven by numerous "Buy" recommendations. While institutional ownership is high, company insiders have sold over 105,000 shares worth $1.43 million in the last 90 days.

Wedbush Adjusts Price Target on ORIC Pharmaceuticals to $14 From $17, Keeps Outperform Rating

https://finance.yahoo.com/markets/stocks/articles/wedbush-adjusts-price-target-oric-090809483.html
Wedbush has lowered its price target for ORIC Pharmaceuticals (ORIC) from $17 to $14 but has maintained its "Outperform" rating on the stock. The article indicates that ORIC Pharmaceuticals has an average "buy" rating among analysts with a mean price target of $21.71. Access to the full details of this report requires a premium subscription.

Stifel maintains Buy rating on ORIC Pharmaceuticals, $18 price target

https://www.tradingview.com/news/tradingview:cb3de3d0e6a3d:0-stifel-maintains-buy-rating-on-oric-pharmaceuticals-18-price-target/
Stifel has reiterated its Buy rating on ORIC Pharmaceuticals, setting an $18 price target, which suggests a 36.7% upside from its recent closing price. This positive outlook is supported by encouraging Phase 1b clinical data for enozertinib in NSCLC, showing an 84% overall response rate and significant CNS activity. Additionally, data from Pfizer's mevrometostat monotherapy has de-risked ORIC's MEVPRO-1 trial, increasing confidence in its rinzimetostat.
Advertisement

Oric Pharmaceuticals Falls 27% After J&J Prostate Cancer Data

https://stockstotrade.com/news/oric-pharmaceuticals-inc-oric-news-2026-10-26/
Oric Pharmaceuticals (NASDAQ: ORIC) stock dropped 27% after Johnson & Johnson released early results for its rival prostate cancer drug, JNJ-6143, raising competition concerns for Oric's Rinzimetostat. J&J's drug showed confirmed complete or partial responses in 75% of patients in a Phase 1 trial, potentially impacting future sales for Oric's experimental treatment. Despite this, Oric continues its development of Rinzimetostat and plans a Phase 3 trial for its lung cancer drug, Enozertinib, in the first half of next year.

Stifel raises ORIC Pharmaceuticals price target to $18 on ESMO data

https://www.investing.com/news/analyst-ratings/stifel-raises-oric-pharmaceuticals-price-target-to-18-on-esmo-data-93CH-4971305
Stifel has increased its price target for ORIC Pharmaceuticals (NASDAQ:ORIC) shares to $18 from $14, maintaining a Buy rating, citing risk reduction from multiple presentations at ESMO, including data for enozertinib, Pfizer’s mevrometostat, and rinzimetostat. The stock is currently trading at $13.17, up 61% year-to-date, with other analysts setting targets between $14 and $27. Stifel remains conservative despite near-term upside potential beyond the new target and notes that ORIC is considered overvalued relative to its Fair Value by InvestingPro, though it boasts a strong balance sheet.

Oric Pharmaceuticals, Inc. Estimates – NASDAQ:ORIC

https://www.tradingview.com/symbols/NASDAQ-ORIC/financials-estimates/
The article provides a financial overview of Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) on TradingView. It offers access to reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics. Users can compare actual results with average, high, and low estimates, and visualize trends over time.

Oric Pharmaceuticals’ Enozertinib Shows 88% Response Rate in EGFR Lung Cancer Study

https://www.tradingview.com/news/marketbeat:0fe4fd1dc094b:0-oric-pharmaceuticals-enozertinib-shows-88-response-rate-in-egfr-lung-cancer-study/
Oric Pharmaceuticals reported updated Phase 1b data for enozertinib in previously untreated advanced non-small cell lung cancer (NSCLC) patients with atypical EGFR mutations, showing an 88% overall response rate and significant intracranial activity. The company plans to initiate a global randomized Phase 3 trial, REDWOOD-1, in the first half of 2027, targeting a potential accelerated approval. Oric estimates a substantial market opportunity for first-line atypical EGFR NSCLC and continues to explore enozertinib for exon 20 insertion NSCLC.

Oric Pharmaceuticals Reports Enozertinib Phase 1b Results, Plans Phase 3 in 2027

https://www.tradingview.com/news/tradingview:6e76e8a1fcc6c:0-oric-pharmaceuticals-reports-enozertinib-phase-1b-results-plans-phase-3-in-2027/
Oric Pharmaceuticals (ORIC) announced positive systemic and intracranial activity from its enozertinib Phase 1b trial, with confirmed systemic ORR of 84% and intracranial ORR of 70% by investigator assessment. The drug was generally well-tolerated. The company plans to initiate a global Phase 3 trial, Redwood-1, in the first half of 2027, enrolling approximately 360 patients with dual primary endpoints.
Advertisement

Form 8K Oric Pharmaceuticals Inc For: 23 October By Investing.com

https://za.investing.com/news/stock-market-news/form-8k-oric-pharmaceuticalsinc-for-23-october-93CH-4522428
This article reports on the filing of a Form 8K by Oric Pharmaceuticals Inc. on October 23, 2026. The brief announcement provides no further details regarding the content of the Form 8K, directing readers to Investing.com for more information.

Form 8K Oric Pharmaceuticals Inc For: 23 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-8k-oric-pharmaceuticalsinc-for-23-october-93CH-2754305
Oric Pharmaceuticals Inc. filed a Form 8K on October 23, 2026, as reported by Investing.com. This filing is a standard requirement for public companies to announce significant events that shareholders should know about. The article provides the basic announcement of the filing without further details about its content.

A lung cancer drug shrank brain tumors in 70% of assessed patients.

https://www.stocktitan.net/news/ORIC/oric-pharmaceuticals-presents-potential-best-in-class-data-for-yjj98eophz5v.html
ORIC Pharmaceuticals (ORIC) announced positive Phase 1b results for its lung cancer drug, enozertinib, which achieved an 84% systemic objective response rate and a 70% intracranial response rate in previously untreated NSCLC patients with EGFR atypical mutations, including those with brain metastases. Based on these promising results, ORIC plans to advance enozertinib into a global Phase 3 trial, Redwood-1, in the first half of 2027, aiming for both accelerated and full approvals. The drug demonstrated a favorable safety profile with predominantly mild to moderate side effects.

ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026

https://www.globenewswire.com/news-release/2026/10/23/3387077/0/en/oric-pharmaceuticals-presents-preclinical-and-translational-data-to-support-the-potential-of-rinzimetostat-to-enhance-sensitivity-to-androgen-receptor-inhibition-in-prostate-cancer.html
ORIC Pharmaceuticals announced preclinical and translational data at the ESMO Congress 2026, highlighting the potential of rinzimetostat to enhance sensitivity to androgen receptor inhibition in prostate cancer. The data suggest advantages of targeting PRC2 via EED with rinzimetostat over EZH2, including sustained effectiveness against resistance mutations and a potentially lower tumorigenesis risk. Findings support rinzimetostat's differentiated profile and its development across the prostate cancer disease spectrum, including in the ongoing Himalayas-1 Phase 3 trial.

A prostate cancer drug may make hormone-blocking treatment work better

https://www.stocktitan.net/news/ORIC/oric-pharmaceuticals-presents-preclinical-and-translational-data-to-pe1vef1dp61w.html
ORIC Pharmaceuticals presented preclinical and translational data at ESMO Congress 2026 for rinzimetostat, indicating its potential to enhance sensitivity to androgen receptor (AR) inhibition in prostate cancer. The data showed that rinzimetostat maintained potency against EZH2 mutations associated with resistance, restricted changes in cell identity, and synergized with AR inhibition in preclinical models. Patient samples also exhibited biological changes consistent with increased AR signaling, supporting further evaluation including in the ongoing Himalayas-1 Phase 3 trial.
Advertisement

ORIC® Pharmaceuticals Presents Potential Best-in-Class Data

https://www.globenewswire.com/news-release/2026/10/23/3387076/0/en/oric-pharmaceuticals-presents-potential-best-in-class-data-for-enozertinib-in-1l-nsclc-patients-with-egfr-atypical-mutations-at-esmo-congress-2026-and-plans-to-advance-enozertinib-.html
ORIC Pharmaceuticals announced potential best-in-class data for enozertinib in first-line NSCLC patients with EGFR atypical mutations at ESMO Congress 2026. The data demonstrated an 84% confirmed systemic ORR and 70% confirmed intracranial ORR, even with a high rate of baseline CNS metastases. Supported by these results, ORIC plans to advance enozertinib into a global Phase 3 registrational trial, Redwood-1, in the first half of 2027.

Form 4 Oric Pharmaceuticals Inc: Dominic Piscitelli (CFO) For: 20 October

https://au.investing.com/news/stock-market-news/form-4-oric-pharmaceuticalsinc-dominic-piscitelli-cfo-for-20-october-93CH-4705919
This article reports on a Form 4 filing for Oric Pharmaceuticals Inc, detailing an insider transaction by Dominic Piscitelli, the Chief Financial Officer, for October 20. The brief piece includes the company's stock symbol (ORIC) and its current price performance.

Oric Pharmaceuticals’ Enozertinib Shows 88% Response Rate in EGFR Lung Cancer Study

https://finance.yahoo.com/healthcare/articles/oric-pharmaceuticals-enozertinib-shows-88-170441108.html
Oric Pharmaceuticals reported strong early efficacy data for enozertinib in previously untreated atypical EGFR-mutated NSCLC, showing an 88% overall response rate and 100% disease control. The drug also demonstrated significant central nervous system activity, with high intracranial response rates in patients with brain metastases. The company plans to initiate a global Phase 3 trial, REDWOOD-1, in the first half of 2027 to compare enozertinib with existing treatments.

Oric Pharma CFO Dominic Piscitelli sells $189,390 in stock

https://www.investing.com/news/insider-trading-news/oric-pharma-cfo-dominic-piscitelli-sells-189390-in-stock-93CH-4964273
Dominic Piscitelli, CFO of Oric Pharmaceuticals, sold 14,000 shares of company stock worth $189,390 on October 20, 2026, after exercising stock options. This transaction occurred as ORIC shares traded near their 52-week high, following a 69% year-to-date return. Analysts maintain optimistic price targets for ORIC Pharmaceuticals, citing progress in its development programs.

Form 4 Oric Pharmaceuticals Inc: Dominic Piscitelli (CFO) For: 20 October

https://ca.investing.com/news/stock-market-news/form-4-oric-pharmaceuticalsinc-dominic-piscitelli-cfo-for-20-october-93CH-4894772
This article reports on a Form 4 filing for Oric Pharmaceuticals Inc., detailing that Dominic Piscitelli, the CFO, had a transaction on October 20. The brief report from Investing.com provides no further details about the nature of the transaction.
Advertisement

Oric Pharmaceuticals (ORIC) CFO exercises 14,000 options and sells shares under a trading plan.

https://www.stocktitan.net/sec-filings/ORIC/form-4-oric-pharmaceuticals-inc-insider-trading-activity-7bc4ccd54e14.html
Oric Pharmaceuticals' CFO, Dominic Piscitelli, exercised 14,000 stock options at $4.36 per share on October 20, 2026, and simultaneously sold 14,000 common shares at a weighted average price of $13.5279 per share. This transaction was conducted under a Rule 10b5-1 trading plan adopted in May 2026. Following these transactions, Piscitelli's reported holdings include 64,500 stock options and 69,828 common shares.

ORIC Pharmaceuticals stock gains 12.10 percent at EUR 12.32

https://www.ad-hoc-news.de/boerse/news/nebenwerte/oric-pharmaceuticals-stock-gains-12-10-percent-at-eur-12-32/70376584
ORIC Pharmaceuticals stock increased by 12.10 percent to EUR 12.32 on October 20, 2026, following JPMorgan's upgrade of its price target from USD 23.00 to USD 26.00. Despite the positive stock performance and analyst rating, the company reported a GAAP net loss of USD 41.49 million for the quarter ended June 30, 2026, highlighting the financial risks associated with a clinical-stage biotechnology firm. The article details the stock's performance, analyst targets, and recent financial results.

ORIC will discuss data on a potential lung cancer treatment Friday.

https://www.stocktitan.net/news/ORIC/oric-pharmaceuticals-to-host-conference-call-webcast-to-review-inte074skmnp.html
ORIC Pharmaceuticals will host a conference call and webcast on October 23, 2026, to review clinical data for enozertinib, a potential lung cancer treatment. The discussion will focus on an ongoing Phase 1b trial in patients with non-small cell lung cancer (NSCLC) carrying atypical EGFR mutations, coinciding with its presentation at the ESMO Congress 2026. Dr. Joshua Sabari will join the call to offer his insights on the data.

BTIG Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $26

https://www.moomoo.com/news/post/1001581745/btig-maintains-oric-pharmaceuticals-oricus-with-buy-rating-maintains-target
BTIG has reiterated its Buy rating for Oric Pharmaceuticals (ORIC.US), maintaining a target price of $26. This indicates a continued positive outlook from the firm regarding the company's stock performance and valuation.

ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026

https://www.globenewswire.com/news-release/2026/10/19/3383372/0/en/oric-pharmaceuticals-to-host-conference-call-webcast-to-review-enozertinib-data-being-presented-at-esmo-congress-2026.html
ORIC Pharmaceuticals will host a conference call and webcast on Friday, October 23, 2026, at 8:00 a.m. ET to discuss enozertinib clinical data. This event coincides with the ESMO Congress 2026, where data from the Phase 1b trial of enozertinib in first-line NSCLC patients with EGFR atypical mutations will be presented. Dr. Joshua Sabari will join ORIC leadership to share insights on the data and enozertinib's potential.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement